SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

Aclaris Therapeutics, Inc. (ACRS)

Add ACRS Price Alert      Hide Sticky   Hide Intro
Search This Board:
Last Post: 9/6/2016 11:44:47 AM - Followers: 1 - Board type: Free - Posts Today: 0
Aclaris Therapeutics, Inc.

101 Lindenwood Drive
Suite 400
Malvern, PA 19355
United States

Aclaris Therapeutics, Inc., a clinical-stage specialty pharmaceutical company, focuses on identifying, developing, and commercializing topical drugs to address various needs in dermatology. Its lead drug candidate is A-101, a hydrogen peroxide topical solution that has completed three Phase II clinical trials for the treatment of seborrheic keratosis (SK), a common non-malignant skin tumor. The company is also developing A-101 as a prescription treatment for common warts; and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts. Aclaris Therapeutics, Inc. was founded in 2012 and is headquartered in Malvern, Pennsylvania.
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
ACRS News: Aclaris Therapeutics Honored as One of the Best Places to Work in Pennsylvania 08:00 AM
ACRS News: Aclaris Therapeutics to Announce Third Quarter 2016 Financial Results on November 3, 2016 10/25/2016 08:00:00 AM
ACRS News: Statement of Changes in Beneficial Ownership (4) 10/20/2016 04:21:53 PM
ACRS News: New Observational Study Demonstrates Patient Impact of Seborrheic Keratosis, A Common, Undertreated Skin Condition Affecting ... 10/19/2016 08:00:00 AM
ACRS News: Amended Statement of Ownership (sc 13g/a) 10/06/2016 04:31:15 PM
News News Alert: Aclaris Therapeutics Honored as One of the Best Places to Work in Pennsylvania 10/28/2016 08:00:00 AM
#1   ACRS bullish 22.07 stocktrademan 09/06/16 11:44:47 AM